Release Date: June 29, 2018
Expiration Date: June 29, 2019
Media: Internet - based
During this Medical Crossfire®, a panel of leading cardiologists and lipid specialists will review the latest indications for PCSK9 inhibitors along with the updated ACC Expert Consensus and National Lipid Association Expert Panel Recommendations incorporating nonstatin therapies into clinical practice. Recent clinical trial data for evolocumab and alirocumab will be reviewed. A brief summary of the FOURIER trial will lead into analysis of new data that identifies high-risk subgroups that demonstrated treatment benefits. ODYSSEY OUTCOMES will be reviewed and the clinical implications of that data will be put it into context with FOURIER results. The final segment will focus on barriers that have prevented the uptake of PCSK9 inhibitors into clinical practice. The panelists will share practical and effective strategies for increasing prior authorization approval rates as well as the need for education on the benefits of nonstatin therapy for both prescribing clinicians and patients.
This activity is supported by an educational grant from Amgen.
Instructions for This Activity and Receiving Credit
This CME activity is primarily intended for lipidologists and cardiologists. Nurses, physician assistants, and other health care professionals interested in the treatment of hypercholesterolemia are also invited to participate.
Upon completion of this CME activity, you should be better prepared to:
DESCRIBE the latest clinical guidelines and recommendations for the use of proprotein convertase subtilisin kexin type 9 inhibitors (PCKS9i)
ELUCIDATE recent findings from cardiovascular outcomes studies of PCSK9i
APPLY the results of PCSK9i cardiovascular outcomes trials to manage patients with high risk of an atherosclerotic cardiovascular event
IMPLEMENT processes that would be expected to improve payer approval of PCSK9i prescriptions
Marc S. Sabatine, MD, MPH
Chairman, TIMI Study Group
Lewis Dexter, MD, Distinguished Chair in Cardiovascular Medicine
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Disclosure: Grant/Research Support: Research grant support through Brigham and Women’s Hospital from Amgen, AstraZeneca, Daiichi Sankyo, Eisai, GlaxoSmithKline, Intarcia, Janssen Research and Development, Medicines Company, MedImmune, Merck, Novartis, Pfizer, Poxel, Takeda; Consultant: Amgen, AstraZeneca, Bristol-Myers Squibb, CVS Caremark, Dyrnamix, Esperion, Intarcia, Janssen Research and Development, Medicines Company, MedImmune, Merck, Novartis
Daniel Soffer, MD, FNLA, FACP
Clinical Associate Professor of Medicine
Perelman School of Medicine
The University of Pennsylvania
Disclosure: Grant/Research Support: Akcea/Ionis, Amgen, AstraZeneca, Kowa, Novartis, Sanofi, Regeneron, Regenix/NIH; Consultant: Akcea, Amgen; Speaker’s Bureau: Akcea, NLA
James Underberg, MD
Immediate Past President of the National Lipid Association
Clinical Assistant Professor of Medicine
New York University School of Medicine
New York, New York
Disclosure: Grant/Research Support: Aegerion, Pfizer; Consultant: Amarin, Amgen; Speaker’s Bureau: Alexion, Amarin, Amgen, Kowa, Regeneron, Sanofi, True Health Diagnostics
Karol Watson, MD, PhD
Professor of Medicine, Cardiology/Cardiovascular Disease
David Geffen School of Medicine at UCLA
Co-director, UCLA Program in Preventive Cardiology
Director, UCLA Barbra Streisand Women’s Heart Health Program
John Mazziotta, MD, PhD, Term Chair in Medicine
Ronald Reagan UCLA Medical Center
Los Angeles, California
Disclosure: Consultant: Amgen, Boehringer Ingelheim/Lily, Kowa
The staff of Physicians' Education Resource®, LLC have no relevant financial relationships with commercial interests.
Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians, and is a provider approved by the California Board of Registered Nursing (CBRN).
Physicians' Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™ and for 1.5 contact hours for nurses. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to the diagnostic, treatment, and management options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
Dec 31, 2018
Medical Crossfire®: Defining New Roles for the Application of PARP Inhibition Strategies in Multiple Tumor Types
Dec 31, 2018
Dec 31, 2018